I took a quick look at one of cenicriviroc's HIV trials. Strangely it shows an increase from 0% baseline in inflammation biomarker MCP-1 to 400% to 800% in 12 weeks (dosage dependent) and that increase starts immediately after treatment. MCP-1 being a monocyte chemoattractant that doesn't seem good. Also patients with hepatitis were excluded from the trial. Being a small molecule blocker like maraviroc it might be causing liver issues.

https://journals.lww.com/aidsonline/fulltext/...ing.6.aspx